Can you comment on the landscape for generic and biosimilar conversions, especially with 16-20 new LDD introductions expected?

The company expects 16-20+ LDD launches in the next 12-18 months, expanding into rare, orphan, and infusion LDDs. They have minimal biosimilar exposure, with STELARA mostly in the rearview mirror, and do not anticipate significant impact from biosimilars. “From a biosimilar perspective, with STELARA mostly in the rearview mirror, there's a little bit of residual impact for us this year. But we really don't have any exposure there just given the nature of the therapies and the drugs that we supply.”

Can you discuss the expected EBITDA and margins for each segment for the upcoming year?

Management expects broad-based margin expansion across segments in FY26 due to initiatives deployed in late FY25 and continuing into FY26, favorable product/service mix, and operational efficiencies. They will continue to invest in AI, technology, and sales for future growth. “We do expect broad-based margin expansion from the initiatives that we've deployed in late 2025 and continuing into 2026.”

What are your views on the future of temporary and permanent behavioral adjustment cuts for home health, given the recent acquisitions?

The company's baseline view for home health rates is flat, to be conservative. They remain optimistic due to constructive conversations and the value of home health, seeing an "unbelievable runway" over the next 5-10 years. They believe there could be positive rate adjustments in the future. “Our baseline view of home health rates, just to be conservative, is flat. I think there's been a lot of constructive conversations even here recently around the future and the value of home health. So we do remain optimistic.”

BTSG

BrightSpring (BTSG) Q4 FY25 earnings call: guidance and Q&A

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 27, 2026

Source: earnings call transcript

Executive summary

BrightSpring Q4 FY25 — Strong Growth, Strategic Divestiture & Acquisitions, and Exceeded Leverage Targets

BrightSpring delivered robust Q4 and full-year FY25 results, driven by strong growth in Pharmacy Solutions and Provider Services, strategic M&A, and operational efficiencies. The company successfully divested its Community Living business and acquired significant home health assets, strengthening its balance sheet and exceeding leverage targets. Management is focused on continued volume growth, margin expansion through efficiency, and integrating new acquisitions, while navigating revenue headwinds from IRA and generic conversions in FY26.

Highlights

Total company revenue grew 29% in Q4 FY25 to $3.6 billion, and 28% for full year FY25 to $12.9 billion.
Adjusted EBITDA grew 41% in Q4 FY25 to $184 million, and 34% for full year FY25 to $618 million.
Leverage ratio decreased to 2.99x as of December 31, 2025, exceeding the target range of 3.0-3.5x.
Acquired 107 Amedisys and LHC home health branches for $239 million, adding $345 million in pro forma FY25 revenue.
Pharmacy Solutions adjusted EBITDA grew 44% in Q4 FY25, with specialty and infusion script growth of 30% YoY.

Concerns

Home and community pharmacy revenue declined 1% YoY in Q4 FY25 due to the unwinding of a large customer bankruptcy and exit of uneconomic customers.
Revenue headwinds of approximately $600 million expected in FY26 from IRA impact ($200M in specialty/infusion, $175M in home/community) and brand-to-generic conversions (over $400M in specialty/infusion).
Home and community script growth will be challenged until Q3 FY26 due to prior customer offboarding.

Guidance & targets

Category	Target	Timeline	Confidence
Total Revenue	$14.45 billion to $15.0 billion high materiality	FY26	High
Pharmacy Solutions Revenue	$12.6 billion to $13.1 billion medium materiality	FY26	High
Provider Services Revenue	$1.85 billion to $1.9 billion medium materiality	FY26	High
Total Adjusted EBITDA	$760 million to $790 million high materiality	FY26	High
EBITDA Contribution from Amedisys and LHC Acquisitions	$30 million medium materiality	FY26	High
Leverage Ratio	2.5x or below high materiality	Midyear · FY26	Medium
Limited Distribution Drug (LDD) Launches	16 to 20 plus medium materiality	Next 12-18 months	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Pharmacy Solutions Adjusted EBITDA margin expanded by approximately 40 basis points versus last year. Total pharmacy script volume was 10.8 million in the quarter, driven by total pharmacy census growth. Total pharmacy volumes declined 1% due to a slight decline in home and community pharmacy volumes from customer bankruptcy and exit of uneconomic customers. Adjusted EBITDA growth: 44% YoYGross profit: $255 millionGross profit growth: 25% YoY	$3.2 billion	32%	—	5.1% adjusted EBITDA margin
Pharmacy Solutions - Infusion and Specialty Performance exceeded expectations, driven by market adoption of existing LDDs, new LDD wins, fee-for-service growth, and strong commercial execution. Infusion business performed in line with expectations with solid script volume growth. Script growth: 30% YoYLDD portfolio: 149New LDD launches in Q4: 5Total LDD launches in FY25: 24	$2.6 billion	43%	—	—
Pharmacy Solutions - Home and Community Pharmacy Revenue declined due to divestitures associated with a customer that declared bankruptcy and decisions to exit specific uneconomic customers. Executed consistently across several end markets including behavioral, assisted living, hospice, and skilled nursing.	$593 million	-1%	—	—
Provider Services Adjusted EBITDA margin expanded by approximately 50 basis points versus last year, primarily driven by economies of scale and efficiency. Adjusted EBITDA growth: 16% YoYGross profit: $158 millionGross profit growth: 17% YoY	$394 million	13%	—	16.4% adjusted EBITDA margin
Provider Services - Home Health Care Represents approximately 55% of Provider segment revenue. Growth driven by strong quality metrics, de novos, partnerships, preferred MA contracts, and strategic tuck-in acquisitions. Over 91% of branches at 4 stars or greater with 99.4% timely initiation of care. Average daily census: almost 35,000Average daily census growth: 15%	$217 million	19%	—	—
Provider Services - Rehab Care Represents approximately 20% of Provider segment revenue. Growth driven by neuro rehab de novo additions, high patient satisfaction scores, and expansion of rehab and motion program into ALF and home settings. Persons served growth: 13%Hours billed growth in neuro rehab services: 17%	$75 million	8%	—	—
Provider Services - Personal Care Represents approximately 25% of Provider segment revenue. Steady operational performance providing high-quality supportive care to seniors. Persons served: 16,175Persons served growth: 2%	$102 million	4%	—	—

BTSG operating KPIs by quarter

BTSG operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	Jun 2026 Q2 FY26	Change vs prior quarter
LDDs	153 We continue to see strong volume performance from both brand LDDs and generics, and we added 4 exclusive and UltraAR LDDs to our portfolio in the first quarter, bringing our total number of LDDs to 153. Source: earnings call transcript	155 During the quarter, we added 2 ultra-narrow network LDDs to our portfolio bringing the total number of LDDs to 155. Source: earnings call transcript	+1.3%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

null Divestiture of Community Living business to streamline operations and focus on core patient populations. $835 million gross cash consideration

The transaction was approved by the FTC. Expected to result in net after-tax cash proceeds of approximately $715 million, which will be primarily utilized for debt paydown to further improve leverage and strengthen the balance sheet.

Amedisys and LHC Acquisition of home health assets to complement existing home health business and expand geographic presence. $239 million purchase price

Acquired 107 branches in a two-part transaction on December 1 and December 31, 2025. Fully funded from cash on hand. Assets are complementary geographically and in the same markets as existing hospice locations.

Risks & headwinds

Decline in home and community pharmacy revenue Q4 FY25, script challenges until Q3 FY26

1% YoY decline in Q4 FY25

Mitigation:Unwinding of a large customer going through bankruptcy and decision to exit specific uneconomic customers. Forward year guidance contemplates various scenarios for the ongoing bankruptcy process. Enhancing go-to-market strategy, investing in growth resources, and driving expansion in end markets.

Revenue headwind from IRA FY26

approximately $200 million

Mitigation:Working productively with payers regarding enhanced dispensing fees to mitigate impact. Government relations team active.

Revenue headwind from brand-to-generic conversions FY26

over $400 million

Mitigation:While revenue declines, margins often improve. Company drives generic utilization and benefits from procurement. Focus on LDD wins and fee-for-service business.

Revenue headwind from IRA FY26

approximately $175 million

Mitigation:Working productively with payers regarding enhanced dispensing fees. Leveraging scale, platform, and operational improvements.

Uncertainty regarding future home health rates Future

Baseline view is flat rates

Mitigation:Optimistic due to constructive conversations and value of home health. See an 'unbelievable runway' over the next 5-10 years. Base case is flat, but potential for positive rate increases.

What to watch in Q1 FY26

Community Living Divestiture

End of Q1 FY26

Current Approved by FTC, expected to close

Target Closed

Why it matters

The closing of this divestiture will provide $715 million in net cash proceeds for debt paydown, significantly impacting the company's leverage and capital allocation flexibility.

Earlier this year, the Community Living divestiture transaction was approved by the FTC, and at this time, we expect the transaction to close at the end of the first quarter.

Find out whether BTSG delivers this. Inve re-checks your case every morning.

Q&A highlights

What are the greatest swing factors that could create upside or challenges for the FY26 guidance?

Management expects consistency, focusing on continued volume growth through sales investments (home health, hospice, infusion, home & community in select markets), realizing benefits from Lean Sigma, tech, and AI projects, and successful integration of Amedisys/LHC acquisitions.

“I mean as we look out for the year and try to ensure execution, continuing to drive volume growth in each of the businesses is going to be important.”

asked by Albert Rice · answered by Jon Rousseau

2 min read 6 chapters

Detailed narrative

Strategic Portfolio Optimization

BrightSpring is streamlining its operations through strategic portfolio adjustments. The divestiture of the Community Living business, approved by the FTC, is expected to close by the end of Q1 FY26, yielding approximately $715 million in net after-tax cash proceeds primarily for debt paydown.

Concurrently, the company acquired 107 Amedisys and LHC home health branches for $239 million, fully funded by cash on hand, which generated $345 million in pro forma FY25 revenue and are expected to contribute $30 million to FY26 adjusted EBITDA.

Strong Financial Performance and Balance Sheet

The company reported robust financial results, with full year FY25 revenue of $12.9 billion (up 28% YoY) and adjusted EBITDA of $618 million (up 34% YoY). Adjusted EBITDA margin expanded by 20 basis points to 4.8%, driven by procurement and operational initiatives.

Operating cash flow reached $490 million in FY25. The leverage ratio significantly improved to 2.99x as of December 31, 2025, down from 4.16x in FY24, surpassing the target of 3.0-3.5x.

Pharmacy Solutions Growth Drivers

Pharmacy Solutions revenue grew 32% in Q4 FY25, with adjusted EBITDA up 44%. Specialty and infusion script growth was 30% YoY, driven by market adoption of existing LDDs, new LDD wins, and fee-for-service growth. The LDD portfolio now stands at 149, with 24 launches in FY25.

The company expects 16-20+ LDD launches over the next 12-18 months, including rare, orphan, and infusion LDDs, expanding beyond oncology.

Provider Services Segment Performance

Provider Services revenue grew 13% in Q4 FY25, with adjusted EBITDA up 16% and a margin of 16.4%, expanding 50 basis points YoY. Home health care, representing 55% of segment revenue, grew 19% with average daily census up 15% to nearly 35,000. Rehab care revenue grew 8% with persons served up 13%, and personal care revenue grew 4% with persons served up 2%.

Operational Excellence and Quality Outcomes

BrightSpring emphasizes its commitment to high-quality, patient-centric care, reflected in strong patient satisfaction scores across all segments. Home health branches maintain over 91% at 4 stars or greater, and hospice metrics are well above national averages. The company continues to invest in technology, AI, and Lean Sigma projects to drive efficiency and enhance operational processes, contributing to margin expansion.

Community Engagement and Foundation Launch

The company highlighted its commitment to employees and communities through various support programs, including college scholarships and nursing school partnerships. BrightSpring has launched an enterprise foundation, the BrightSpring Health Foundation, to formally carry on its community and patient support activities, aiming to positively impact lives for decades to come.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.